High Levels Of Serum CXCL13 Among Patients With Early RA Are Predictive Of Reduced Response To Methotrexate, Study Finds

Rheumatology Advisor (12/30, Saha) reports, “High levels of serum C-X-C motif chemokine 13 (CXCL13) among patients with early rheumatoid arthritis (RA) are predictive of a reduced response to methotrexate, according to study findings.” Investigators came to this conclusion after analyzing data on “243 patients aged an average of 59.3 years.” The research was published in Rheumatology.